Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01517334 · ClinicalTrials.gov registry record · Phase 3

Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)

A Phase 3 study of Peri Implantitis, sponsored by OraPharma.

Completed
Registry status
Phase 3
Development phase
208
Enrollment target
10
Study locations

NCT01517334 is a Phase 3 study of Peri Implantitis that has completed, run by OraPharma. The registered enrollment target is 208 participants, above the 68-participant average among 4 other Peri Implantitis trials with a reported enrollment target (206% higher). The trial reports 10 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01517334, a Phase 3 study of Peri Implantitis, has completed, sponsored by OraPharma.

COMPLETED
Registry status
Phase 3
Development phase
208 participants
Enrollment target
10
Study locations

Study Summary

The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in combination with mechanical debridement is more effective in the treatment of peri-implantitis when compared to mechanical debridement alone. The primary efficacy measure will be the reduction of probing depth at Day 180 as measured at qualifying implant sites.

Conditions Studied

Interventions

  • DRUG Minocycline HCl Microspheres

Study Locations (10)

Maryland

  • University of Maryland, School of Dentistry - Baltimore

Massachusetts

  • Tufts University School of Dental Medicine - Boston

Michigan

  • University of Michigan - Michigan Center for Oral Health Research - Ann Arbor

Missouri

  • University of Missouri - Kansas City School of Dentistry Clinical Research Center - Kansas City

North Carolina

  • University of North Carolina at Chapel Hill School of Dentistry - Chapel Hill

Pennsylvania

  • University of Pennsylvania School of Dental Medicine - Philadelphia

South Carolina

  • Medical University of South Carolina College of Dental Medicine - Charleston

Tennessee

  • UTHSC - College of Dentistry - Memphis

Trial Details

FieldValue
Enrollment Target 208 participants
Start Date 2012-05
Est. Completion 2014-11
Phase Phase 3

Sponsor

OraPharma

5 total trials

What the Registry Record Tells You About NCT01517334

The ClinicalTrials.gov registry entry for NCT01517334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 68-participant average among 4 other Peri Implantitis trials with a reported enrollment target (206% higher). The listed sponsor is OraPharma, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Peri Implantitis appearing as the primary indexed condition, and to 1 intervention - of which Minocycline HCl Microspheres is the first listed.

NCT01517334 reports 10 study locations spanning 10 distinct geographic areas - top geographies include Maryland, Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT01517334 about?

NCT01517334 is a clinical study titled "Arestin - Use in Subjects With Peri-Implantitis (With Subgingival Microbiological Evaluation)". The objective of the study is to evaluate the safety, effectiveness and anti-microbial effects of Arestin (minocycline HCl) 1 mg Microspheres in the treatment of subjects with peri-implantitis, when used in combination with mechanical debridement. The hypothesis of the study is that Arestin in comb...

What is the current status of trial NCT01517334?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2012-05. Estimated completion is 2014-11.

What conditions does trial NCT01517334 study?

This clinical trial studies the following conditions: Peri Implantitis.

What interventions are being tested in trial NCT01517334?

The interventions under investigation include: Minocycline HCl Microspheres (DRUG).

Who is sponsoring clinical trial NCT01517334?

This trial is sponsored by OraPharma, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01517334 being conducted?

This trial has 10 study locations across Maryland, Massachusetts, Michigan, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peri Implantitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.